Q4 FY-2025 Earnings Call Forward Looking Statements Statements in this presentation which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's industry, business, long-term growth prospe ...

Strategic Partnership with DHL Group - Cryoport is strategically pivoting to enable the next phase of global Cell and Gene Therapy (CGT) expansion by leveraging DHL's network[5] - The partnership with DHL provides a more competitively priced, integrated solution to the CGT market, especially in the APAC and EMEA regions[5] - The transaction with DHL generates substantial cash and strengthens Cryoport's balance sheet, improving revenue growth rate and gross margin profile[5] Financial Highlights and Projections - Cryoport's new FY 2025 revenue guidance is projected to be between $165 million and $172 million, representing a 6%-10% year-over-year growth[35, 36] - Investments into CGT rose to $15.2 billion in 2024, a 30% year-over-year increase[25] - The divestiture of the specialty courier business to DHL Group yielded $195 million in cash (Enterprise Value), a 2.7x multiple of FY'24 revenue[33] CGT Market and Cryoport's Position - The number of Cell & Gene Therapies approved in FY2024 was 8[15] - Cryoport's clinical trial market share has increased to 70%[15] - Commercial Cell & Gene Therapies revenue reached $26 million[20]